Intensive CBT for PTSD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two methods of delivering intensive cognitive-behavioral therapy (CBT) for individuals with PTSD and anxiety disorders. It aims to determine whether CBT in individual or group formats can improve anxiety and life quality more effectively than usual care. Participants will be randomly assigned to receive either individual therapy sessions over two weeks, group therapy over two days, or continue with their usual treatment. Veterans or service members with a current anxiety disorder and moderate-to-poor life enjoyment may be suitable candidates for this study. As an unphased trial, it offers participants the chance to contribute to innovative research that could enhance future treatment options for anxiety disorders.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you must be stable on psychotropic medication for 4 weeks before participating. This suggests you can continue your current medications if they have been stable for that period.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that intensive cognitive-behavioral therapy (CBT) effectively and safely treats PTSD. Studies have found that intensive CBT, whether in groups or individually, can improve PTSD symptoms and works as well as traditional weekly sessions. Most people find these treatments manageable.
For group-based intensive CBT, research on similar programs has demonstrated good satisfaction, high completion rates, and noticeable symptom improvement. Participants in these studies did not report significant negative effects, supporting the therapy's safety.
Similarly, individual-based intensive CBT has produced promising results. It significantly reduces symptoms, especially for conditions like panic disorder and PTSD. Like the group version, it is considered safe, with few negative effects reported.
Overall, both forms of intensive CBT in this trial appear to be safe options based on existing research. Participants can expect a well-tolerated experience with potential symptom improvements.12345Why are researchers excited about this trial?
Researchers are excited about Intensive Transdiagnostic Cognitive Behavioral Therapy (iTCBT) for PTSD because it offers a more rapid and flexible approach compared to standard treatments like prolonged exposure therapy or conventional CBT. The iTCBT comes in two flavors: a group format (iTCBT-G) and an individual format (iTCBT-I), both designed to deliver the same therapeutic content but in different settings. These treatments are intensive, aiming to deliver results in just two weeks, which is notably quicker than traditional methods that often take several months. This approach not only focuses on alleviating PTSD symptoms but also targets other co-occurring mental health issues, thanks to its transdiagnostic nature. For patients who don't initially respond, there's an enhanced version offering additional sessions to further tailor the treatment to individual needs.
What evidence suggests that this trial's treatments could be effective for PTSD and anxiety disorders?
Research has shown that cognitive-behavioral therapy (CBT) effectively treats PTSD and anxiety. In this trial, participants will receive different forms of intensive CBT. The iTCBT-G arm involves group sessions, while the iTCBT-I arm provides individual sessions. Both approaches have greatly improved PTSD symptoms and overall quality of life. Additionally, methods effective for multiple disorders, such as anxiety and depression, have shown promising results. Overall, CBT is considered a top treatment for these conditions, and evidence supports its effectiveness.13567
Who Is on the Research Team?
Ellen Teng, PhD
Principal Investigator
Michael E. DeBakey VA Medical Center
Are You a Good Fit for This Trial?
This trial is for veterans and service members over 18 with an anxiety disorder like PTSD, panic disorder, or social anxiety. They should have moderate-to-poor life satisfaction and be stable on any psychotropic medication for at least 4 weeks. Participants must be open to random treatment assignment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive iTCBT in either individual or group formats. Individual format involves 12 hours over 2 weeks, while group format involves 12 hours over 2 days.
Enhanced Treatment
For treatment non-responders, 4 additional 90-minute individual therapy sessions are provided over 2 weeks.
Follow-up
Participants are monitored for changes in anxiety and quality of life at 3- and 6-month intervals.
What Are the Treatments Tested in This Trial?
Interventions
- iTCBT-G
- iTCBT-I
- TAU
- Transdiagnostic Cognitive Behavioral Therapy
iTCBT-G is already approved in United States, European Union for the following indications:
- Post-Traumatic Stress Disorder (PTSD)
- Anxiety Disorders
- Post-Traumatic Stress Disorder (PTSD)
- Anxiety Disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
United States Department of Defense
Collaborator